Valneva shares jump 10.14% premarket after launching Brazil chikungunya vaccine pilot with Instituto Butantan.

Valneva surged 10.14% in premarket trading following the announcement of a Brazil pilot vaccination campaign with Instituto Butantan using its chikungunya vaccine IXCHIQ. The program, launched in partnership with the Brazilian Ministry of Health, aims to donate up to 500,000 doses to assess real-world efficacy and safety in selected municipalities. This initiative builds on IXCHIQ’s 2025 market authorization in Brazil, the first approval for a chikungunya vaccine in an endemic country. The move signals progress in commercialization and post-marketing data generation, addressing growing global concerns over chikungunya outbreaks. Positive sentiment was further reinforced by Valneva’s strategic collaboration with Butantan, which includes technology transfer and local production, aligning with public health priorities in tropical regions.